創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 18/08/07 | GEM035 | An anti-ENO1 antibody | Immune diseases, various cancers | SC | Protein |
Preclinical （close to IND） | Showed efficacy in animal models of multiple sclerosis, RA, pancreatic cancer and liver cancer. Also applicable to IBD and COPD etc. Completed pre-clinical studies including monkey toxicity studies, GMP production. |
問合せ |
| 18/08/07 | GEM034 | Derivative of neuroprotective protein | Stroke, Huntington chorea, Schizophrenia and PTSD | IV | Peptide |
Preclinical | A cell-permeable recombinant peptide. Can cross the blood-brain barrier, is resistant to degradation, and can bind constitutively to its substrates. Significantly reduces brain damage in rodent stroke model. Expected to be treated after stroke without diagnosis of stroke type before dosing. |
問合せ |
| 18/08/07 | GEM033 | Inhibitors of bacterial resistance mechanisms | Gram-negative MDR bacterial infections, lung infections in cystic fibrosis （CF） patients | see Note | Small molecule |
Preclinical | Restore effectiveness of shelved antibiotics. Lower the effective dose of antibiotics. Mitigate antibiotic resistance. Disrupt biofilm-based infections. Over 1,000 compounds with lead compounds for each indication identified. Route : Intravenous, Aerosol, Topical |
問合せ |
| 18/07/26 | GEM032 | Calcium release-activated calcium channel inhibitor | Respiratory & immuno-inflammatory diseases | Oral | Small molecule |
Phase 1 | - Preclinical study demonstrated the therapeutic potential in respiratory diseases causally associated with allergic inflamation. - Phase 1 SAD/MAD study were completed. |
問合せ |
| 18/07/26 | GEM031 | Store-Operated Calcium Entry (SOCE) Inhibitor | Lymphomas & Solid cancer | Oral | Small molecule |
Phase 1 | - Demonstrated preclinical activity in a broad range of cancers. - Phase 1 dose-escalation study in patients with relapsed or refractory lymphomas is ongoing. |
問合せ |
| 18/07/26 | GEM030 | PI3K δ/γ dual inhibitor | Hematological malignancies, T cell Lymphoma, Hodgkin Lymphoma | Oral | Small molecule |
Phase 2 | - Highly specific dual PI3K δ/γ inhibitor with nano‐molar inhibitory potency - Single-agent and combination with immune checkpoint inhibitor programs - Inhibits primary patient leukemic/lymphoma cells - Dose escalation study demonstrated an acceptable safety and tolerability with promising clinical activity |
問合せ |
| 18/07/20 | GEM029 | A cancer stem cell-associated transcription factor inhibitor | Malignant gliomas including glioblastoma （GBM） | Oral | Small molecule |
Phase 1 ready | -Directly kills the cancer stem cells. -Significantly improves survival in orthotopic GBM PDX models. -Inhibits tumor growth in a mouse implanted with GBM cells and the growth inhibition is augmented by combination with temozolomide/radiation. -No significant toxicities are identified at therapeutic doses. |
問合せ |
| 18/07/09 | GEM028 | miRNA targeting refractory colon cancer with mutated K-ras and refractory pancreatic cancer | pancreatic cancer colon cancer | IV | Nucleic acid |
Preclinical | The miRNA regulates K-ras, Bcl2, survivin, and NF-kB and demonstrate excellent antitumor effect in vitro and in vivo. | 問合せ |
| 18/07/09 | GEM027 | miRNA targeting refractory colon cancer with mutated K-ras | colon cancer | IV | Nucleic acid |
Preclinical | The miRNA regulates EGFR signaling pathway by directly inhibiting of both KRAS and AKT1 and demonstrate excellent antitumor effect in vitro and in vivo. | 問合せ |
| 18/07/09 | GEM026 | siRNA suppressing the expression of novel cancer stem cell gene "Gene A" | Cancer | IV | Nucleic acid |
Preclinical | -Novel cancer stem cell gene "Gene A", which was discovered by single cell analysis of cancer stem cell, shows character as follows. 1.Superior cancer stem cell diagnostic marker than known cancer stem cell marker CD44v9 2.SiRNA targeting Gene A demonstrate excellent antitumor effect with currnet medicines. |
問合せ |